Ganglioside as a drug for psoriasis

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10255
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Dermatology
• Research Institution: Teikyo University
• Principal Investigator: Tada Yayoi 帝京大学, 医学部, 主任教授 (00334409)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 乾癬

Outline of Final Research Achievements

Psoriasis is a disease of Th1 and Th17 immune response. Here, we investigated the role of ganglioside of suppressing the immune response of psoriasis. IMQ applied mice was used as a psoriasis mouse model. Ganglioside GM1,GM2,GD1a,GD3,GT1b decreased the skin erythema, epidermal thickness, scale of these mice, and histopathology showed that ganglioside decreased the infiltrating T cells. Cytokine and chemokine expression of the skin , such as TNF,CXCL1/2, IL-17A, IL-22, IL-12p40, IL-23p19, CCL20 and anti microbial peptide DEFB4 expression was decreased by mRNA level. Therefore, our result suggested that IMQ suppressed and improved psoriasis like inflammation of psoriasis mice model.

Free Research Field

皮膚科学

Academic Significance and Societal Importance of the Research Achievements

乾癬は慢性の炎症生皮膚疾患であるが、マウスの乾癬モデルを用いた我々の研究はガングリオシドがその治療薬として用いられる可能性を示すことができた。